Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies
JournalTrends in Molecular Medicine
MetadataShow full item record
AbstractSystemic lupus erythematosus (SLE) is a multisystem, chronic autoimmune disease where treatment varies by patient and disease activity. Strong preclinical results and clinical correlates have motivated development of many drugs, but many of these have failed to achieve efficacy in clinical trials. FDA approval of belimumab in 2011 was the first successful SLE drug in nearly six decades. In this article, we review insights into the molecular and clinical heterogeneity of SLE from transcriptomics studies and detail their potential impact on drug development and clinical practices. We critically examine the pipeline of SLE drugs, including past failures and their associated lessons and current promising approaches. Finally, we identify opportunities for integrating these findings and drug development with new multidisciplinary advances to enhance future SLE treatment. Copyright 2020 Elsevier Ltd
systemic lupus erythematosus
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15332
- The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus.
- Authors: Catalina MD, Owen KA, Labonte AC, Grammer AC, Lipsky PE
- Issue date: 2020 Jun
- From old concerns to new advances and personalized medicine in lupus: The end of the tunnel is approaching.
- Authors: Doria A, Gershwin ME, Selmi C
- Issue date: 2016 Nov
- Biologics in SLE: the current status.
- Authors: Rajadhyaksha AG, Mehra S, Nadkar MY
- Issue date: 2013 Apr
- Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.
- Authors: Bakshi J, Segura BT, Wincup C, Rahman A
- Issue date: 2018 Dec
- Dendritic cells as key players in systemic lupus erythematosus.
- Authors: Kaewraemruaen C, Ritprajak P, Hirankarn N
- Issue date: 2020 Dec